Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YP05002 SAD and MAD Study in Healthy Participants
NCT07089823Phase 1Completed
- Sponsor
- Yaoyou Pharmaceutical
- Start
- Aug 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of YP05002 in obesity (8 cohorts), sponsored by Yaoyou Pharmaceutical. Primary endpoint: Number and percentage of adverse events (AEs) and serious adverse events (SAEs) at 14 days. Started Aug 2025; status: completed.
02
Drugs
YP05002
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07089823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07089823.